Brokerage Overview of: Axovant Sciences Ltd. (NYSE:AXON)


Axovant Sciences Ltd. (NYSE:AXON) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Axovant Sciences Ltd. (NYSE:AXON) lost -0.49 Percent and closed its previous trading session at $4.08. The stock traded with the average Volume of 4.89 Million at the end of last session.

The company reported its last earnings Actual EPS of $-0.54/share. While, the analyst predicted that the company could provide an EPS of $-0.5/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.04/share which shows an Earnings Surprise of -8 Percent.

Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Axovant Sciences Ltd. (NYSE:AXON) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 84.09% where SMA50 and SMA200 are 157.67% and -21.19% respectively.

The company shows its Return on Assets (ROA) value of -102.3%. The Return on Equity (ROE) value stands at -168.6%.

Axovant Sciences Ltd. (NYSE:AXON) currently has a Weekly Volatility of 21.15% percent while its Monthly Volatility is at 17.03% percent. While talking about Performance of the Stock, Axovant Sciences Ltd. currently has a Weekly performance of -10.33%, monthly performance percentage is 231.71 percent, Quarterly performance is 172 percent, 6 months performance shows a percent value of -22.58% and Yearly Performance is -81.87 percent.

Company Profile:

Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.